Bellicum Pharmaceuticals, Inc. (BLCM) to Post FY2017 Earnings of ($2.93) Per Share, SunTrust Banks Forecasts
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) – Analysts at SunTrust Banks upped their FY2017 earnings estimates for shares of Bellicum Pharmaceuticals in a research report issued to clients and investors on Tuesday. SunTrust Banks analyst P. Lawson now expects that the biopharmaceutical company will post earnings per share of ($2.93) for the year, up from their prior estimate of ($3.09). SunTrust Banks also issued estimates for Bellicum Pharmaceuticals’ Q4 2017 earnings at ($0.69) EPS, Q2 2018 earnings at ($0.84) EPS, Q3 2018 earnings at ($0.87) EPS, Q4 2018 earnings at ($0.84) EPS, FY2018 earnings at ($3.35) EPS, FY2019 earnings at ($2.36) EPS and FY2020 earnings at ($1.06) EPS.
Several other research analysts also recently weighed in on BLCM. Raymond James Financial, Inc. set a $18.00 target price on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th. ValuEngine downgraded Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, August 11th. Jefferies Group LLC reaffirmed a “buy” rating and set a $16.00 target price (down from $18.00) on shares of Bellicum Pharmaceuticals in a research note on Thursday, August 10th. BidaskClub downgraded Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Finally, Zacks Investment Research raised Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $26.20.
TRADEMARK VIOLATION WARNING: “Bellicum Pharmaceuticals, Inc. (BLCM) to Post FY2017 Earnings of ($2.93) Per Share, SunTrust Banks Forecasts” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.watchlistnews.com/bellicum-pharmaceuticals-inc-blcm-to-post-fy2017-earnings-of-2-93-per-share-suntrust-banks-forecasts/1697110.html.
Bellicum Pharmaceuticals (NASDAQ BLCM) opened at $10.38 on Friday. The company has a current ratio of 6.08, a quick ratio of 8.34 and a debt-to-equity ratio of 0.23. Bellicum Pharmaceuticals has a 52 week low of $7.41 and a 52 week high of $23.11.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.03. The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.03 million. Bellicum Pharmaceuticals had a negative return on equity of 77.16% and a negative net margin of 17,957.31%. The business’s quarterly revenue was up 18.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.66) EPS.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Harvey Capital Management Inc. acquired a new position in Bellicum Pharmaceuticals in the 3rd quarter valued at $458,000. D.A. Davidson & CO. raised its stake in Bellicum Pharmaceuticals by 17.4% in the 3rd quarter. D.A. Davidson & CO. now owns 47,650 shares of the biopharmaceutical company’s stock valued at $550,000 after purchasing an additional 7,050 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Bellicum Pharmaceuticals in the 3rd quarter valued at $189,000. Commonwealth Equity Services Inc acquired a new position in Bellicum Pharmaceuticals in the 3rd quarter valued at $142,000. Finally, California State Teachers Retirement System raised its stake in Bellicum Pharmaceuticals by 16.7% in the 2nd quarter. California State Teachers Retirement System now owns 48,146 shares of the biopharmaceutical company’s stock valued at $562,000 after purchasing an additional 6,900 shares during the last quarter. 55.87% of the stock is owned by hedge funds and other institutional investors.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.